Epkinly gets a second-line follicular nod
And AbbVie and Genmab scoop their ASH presentation with new data.
Zymeworks moves to repeat the Ziihera trick
The company adds royalty aggregation to its R&D business.
FDA red and green lights: October 2025
Syndax’s Revuforj beats Kura in NPM1-mutated AML.
